Add to ORKGJAK2 (V617F), a CALR exon 9 indel, an MPL exon 10 mutation, or none of these genetic lesions. The genetic subtypes of PMF differ substantially as regards clinical course, disease progression, and overall survival. We studied the impact of driver mutations of JAK2, CALR, (calreticulin gene) or MPL on clinical course, leukemic transformation, and survival of patients with primary myelo-fibrosis (PMF). Of the 617 subjects studied, 399 (64.7%) carried JAK2 (V617F), 140 (22.7%) had a CALR exon 9 indel, 25 (4.0%) carried an MPL (W515) mutation, and 53 (8.6%) had nonmutated JAK2, CALR, and MPL (so-called triple-negative PMF). Patients with CALR mutation had a lower risk of developing anemia, thrombocytopenia, and marke
Among classical BCR-ABL-negative myeloproliferative neoplasms (MPN), primary myelofibrosis (PMF) is ...
Mutations in the gene calreticulin (CALR) were recently discovered in 60-80% of patients (pts) with ...
BACKGROUND: Philadelphia negative myeloproliferative neoplasms (MPNs) are characterized by frequent ...
We studied the impact of driver mutations of JAK2, CALR, (calreticulin gene) or MPL on clinical cour...
Calreticulin (CALR) mutations were recently described in JAK2 and MPL unmutated primary myelofibrosi...
Our understanding of the genetic basis of myeloproliferative neoplasms began in 2005, when the JAK2 ...
Mutations of JAK2V617F, CALR, and MPL genes confirm the diagnosis of myeloproliferative neoplasm (MP...
Somatic mutations in CALR gene have been reported in 60%–88% of patients with essential thrombocythe...
Objective: Calreticulin (CALR) plays important roles in cell proliferation, apoptosis, and immune re...
Somatic mutations in the calreticulin (CALR) gene were recently discovered in patients with sporadic...
International audienceMyeloproliferative neoplasms are clonal hematopoietic stem cell disorders char...
BACKGROUND: Approximately 50 to 60% of patients with essential thrombocythemia or primary myelofi...
Janus kinase 2 (JAK2) and calreticulin (CALR) constitute the two most frequent mutations in essentia...
Introduction. JAK2V617F mutation is detected in approximately 50 % of patients with essential thromb...
During the past 10 years, major progress has been accomplished with the discovery of activating muta...
Among classical BCR-ABL-negative myeloproliferative neoplasms (MPN), primary myelofibrosis (PMF) is ...
Mutations in the gene calreticulin (CALR) were recently discovered in 60-80% of patients (pts) with ...
BACKGROUND: Philadelphia negative myeloproliferative neoplasms (MPNs) are characterized by frequent ...
We studied the impact of driver mutations of JAK2, CALR, (calreticulin gene) or MPL on clinical cour...
Calreticulin (CALR) mutations were recently described in JAK2 and MPL unmutated primary myelofibrosi...
Our understanding of the genetic basis of myeloproliferative neoplasms began in 2005, when the JAK2 ...
Mutations of JAK2V617F, CALR, and MPL genes confirm the diagnosis of myeloproliferative neoplasm (MP...
Somatic mutations in CALR gene have been reported in 60%–88% of patients with essential thrombocythe...
Objective: Calreticulin (CALR) plays important roles in cell proliferation, apoptosis, and immune re...
Somatic mutations in the calreticulin (CALR) gene were recently discovered in patients with sporadic...
International audienceMyeloproliferative neoplasms are clonal hematopoietic stem cell disorders char...
BACKGROUND: Approximately 50 to 60% of patients with essential thrombocythemia or primary myelofi...
Janus kinase 2 (JAK2) and calreticulin (CALR) constitute the two most frequent mutations in essentia...
Introduction. JAK2V617F mutation is detected in approximately 50 % of patients with essential thromb...
During the past 10 years, major progress has been accomplished with the discovery of activating muta...
Among classical BCR-ABL-negative myeloproliferative neoplasms (MPN), primary myelofibrosis (PMF) is ...
Mutations in the gene calreticulin (CALR) were recently discovered in 60-80% of patients (pts) with ...
BACKGROUND: Philadelphia negative myeloproliferative neoplasms (MPNs) are characterized by frequent ...